Remove Applications Remove Licensing Remove Pharmaceuticals
article thumbnail

Navigating the cloud maze: A 5-phase approach to optimizing cloud strategies

CIO Business Intelligence

It prevents vendor lock-in, gives a lever for strong negotiation, enables business flexibility in strategy execution owing to complicated architecture or regional limitations in terms of security and legal compliance if and when they rise and promotes portability from an application architecture perspective.

Cloud 245
article thumbnail

What is NLP? Natural language processing explained

CIO Business Intelligence

NLP applications Machine translation is a powerful NLP application, but search is the most used. Transformer models take applications such as language translation and chatbots to a new level. Licensed by MIT, SpaCy was made with high-level data science in mind and allows deep data mining. Amazon Comprehend.

Course 355
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Merck Life Sciences banks on RPA to streamline regulatory compliance

CIO Business Intelligence

The pharmaceutical industry is a highly regulated one, especially for multinationals doing business across the globe. Merck Life Sciences, a leading chemical and pharmaceutical company, with 60,000 employees working across 66 countries, was one of them. Dependency on human resources is both time-consuming and fraught with errors.

Banking 245
article thumbnail

It’s not your data. It’s how you use it. Unlock the power of data & build foundations of a data driven organisation

CIO Business Intelligence

It argues that enterprises need to adopt a three-step process that has traditionally required three distinct products (historically from three separate vendors) to execute analytics effectively and to: ingest and integrate data from enterprise applications, typically using extract, transform and load (ETL) tools. Pharmaceutical research.

Data 245
article thumbnail

Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch

GeekWire

Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. Icosavax filed a clinical trial application in Belgium in June for its RSV candidate and plans to initiate trials later this year, according to a company filing with the U.S. Icosavax Photo).

article thumbnail

Nvidia accelerates enterprise adoption of generative AI

CIO Business Intelligence

Nvidia AI Foundations is a family of cloud services with which enterprises will be able to build their own large language models (LLMs), the technologies at the heart of generative AI systems, and run them at scale, calling them from enterprise applications via Nvidia’s APIs.

article thumbnail

Seattle startup TwinStrand raises $50M to expand tech that identifies rare genetic mutants

GeekWire

Real-world applications: The technology can be used for early cancer detection, searching for cancer cells that survive despite treatment, and monitoring for cancer recurrence. The startup is planning similar licensing deals with other companies that will be announced later this year, Salk said.